Genolution Inc. - Asset Resilience Ratio
Genolution Inc. (225220) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 225220 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Genolution Inc.'s Asset Resilience Ratio has changed over time. See 225220 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Genolution Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genolution Inc. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.79 Billion | 3.8% |
| Total Liquid Assets | ₩3.79 Billion | 3.80% |
Asset Resilience Insights
- Limited Liquidity: Genolution Inc. maintains only 3.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genolution Inc. Industry Peers by Asset Resilience Ratio
Compare Genolution Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 35.56% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Genolution Inc. (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Genolution Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.20% | ₩33.21 Billion ≈ $22.51 Million |
₩106.45 Billion ≈ $72.14 Million |
-6.49pp |
| 2023-12-31 | 37.69% | ₩42.75 Billion ≈ $28.97 Million |
₩113.44 Billion ≈ $76.88 Million |
-2.82pp |
| 2022-12-31 | 40.51% | ₩46.37 Billion ≈ $31.42 Million |
₩114.45 Billion ≈ $77.56 Million |
-7.87pp |
| 2021-12-31 | 48.38% | ₩45.93 Billion ≈ $31.13 Million |
₩94.94 Billion ≈ $64.34 Million |
-10.06pp |
| 2020-12-31 | 58.44% | ₩48.96 Billion ≈ $33.18 Million |
₩83.77 Billion ≈ $56.77 Million |
+30.02pp |
| 2019-12-31 | 28.42% | ₩3.82 Billion ≈ $2.59 Million |
₩13.43 Billion ≈ $9.10 Million |
-18.57pp |
| 2018-12-31 | 46.99% | ₩5.21 Billion ≈ $3.53 Million |
₩11.10 Billion ≈ $7.52 Million |
+1.21pp |
| 2017-12-31 | 45.78% | ₩2.15 Billion ≈ $1.46 Million |
₩4.71 Billion ≈ $3.19 Million |
-12.50pp |
| 2016-12-31 | 58.28% | ₩2.33 Billion ≈ $1.58 Million |
₩3.99 Billion ≈ $2.71 Million |
-- |
About Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more